Leaflet AGGRASTAT 0.25mg / ml concentrate for solution for infusion
Indicated for: prevention of atherothrombotic events
Route of administration: infusion
Substance: tirofiban (antiplatelet agent)
ATC: B01AC17 (Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin)
This medicine may have important interactions with other medicines.
This medicine may increase the risk of bleeding.
Tirofiban is a glycoprotein IIb/IIIa receptor inhibitor used to prevent thrombotic complications in patients with acute coronary syndromes, including unstable angina and non-ST-elevation myocardial infarction (NSTEMI). It works by blocking platelet aggregation, reducing the risk of blood clot formation.
The medication is administered intravenously, usually in combination with other antithrombotic therapies, as directed by a doctor. The dosage is adjusted based on the patient's weight and clinical condition.
Patients should be closely monitored to detect potential side effects, such as bleeding, hypotension, or allergic reactions. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include bleeding, nausea, fever, and headache. In rare cases, severe reactions such as major hemorrhages or thrombocytopenia may occur. Patients should be informed of these risks before starting treatment.
General data about AGGRASTAT 0.25mg / ml
- Substance: tirofiban
- Date of latest medicines list: 01-07-2013
- Product code: W54817001
- Concentration: 0.25mg / ml
- Pharmaceutical form: concentrate for solution for infusion
- Quantity: 1
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.